Clinical Trial Update: A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma [Phase 2]

View source ↗

Summary

Phase IIb study of a drug coded as 610 in participants with severe eosinophilic asthma is ongoing (Phase 2, active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• 610

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Asthma | Phase 2 | Status: ACTIVE_NOT_RECRUITING